Vera Therapeutics, Inc. (VERA) Stock Ticker
VERA right now
Market factors today
Unlock the full VERA picture
About Vera Therapeutics, Inc.
Vera Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of treatments for significant immunological disorders, primarily within the United States. Their leading therapeutic candidate is atacicept, a fusion protein that patients self-administer as a subcutaneous injection. This drug is currently undergoing Phase IIb clinical trials to treat immunoglobulin A nephropathy. The company is also advancing MAU868, a monoclonal antibody in Phase 2 clinical development, designed to combat BK viremia infections. Founded in 2016 and based in Brisbane, California, the organization operated as Trucode Gene Repair, Inc. until it rebranded to Vera Therapeutics, Inc. in April 2020.
VERA stock facts
| Ticker symbol | VERA |
| Exchange | NASDAQ Global Market |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $2.3B |
| CEO | Marshall Fordyce |
| Employees | 361 |
| Headquarters | Brisbane, CA, US |
| IPO date | 2021-05-14 |
| Website | veratx.com |
What you can see for VERA on Tickr
Live VERA price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the VERA report.
Rankings
FAQ
What is the ticker symbol for Vera Therapeutics, Inc.?
The ticker symbol for Vera Therapeutics, Inc. is VERA, listed on the NASDAQ Global Market.
What is VERA?
Vera Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of treatments for significant immunological disorders, primarily within the United States. Their leading therapeutic candidate is atacicept, a fusion protein that patients self-administer as a subcutaneous injection. This drug is currently undergoing Phase IIb clinical trials to…